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Abstract
Introduction: Worldwide, trauma is a leading cause of death and disability. Haemorrhage is responsible for up to
40% of trauma deaths. Recent strategies to improve mortality rates have focused on optimal methods of early
hemorrhage control and correction of coagulopathy. We undertook a systematic review of randomized controlled
trials (RCT) which evaluated trauma patients with hemorrhagic shock within the first 24 hours of injury and
appraised how the interventions affected three outcomes: bleeding and/or transfusion requirements; correction of
trauma induced coagulopathy and mortality.
Methods: Comprehensive searches were performed of MEDLINE, EMBASE, CENTRAL (The Cochrane Library Issue 7,
2010), Current Controlled Trials, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry
Platform (ICTRP) and the National Health Service Blood and Transplant Systematic Review Initiative (NHSBT SRI) RCT
Handsearch Database.
Results: A total of 35 RCTs were identified which evaluated a wide range of clinical interventions in trauma
hemorrhage. Many of the included studies were of low methodological quality and participant numbers were
small. Bleeding outcomes were reported in 32 studies; 7 reported significantly reduced transfusion use following a
variety of clinical interventions, but this was not accompanied by improved survival. Minimal information was
found on traumatic coagulopathy across the identified RCTs. Overall survival was improved in only three RCTs: two
small studies and a large study evaluating the use of tranexamic acid.
Conclusions: Despite 35 RCTs there has been little improvement in outcomes over the last few decades. No clear
correlation has been demonstrated between transfusion requirements and mortality. The global trauma community
should consider a coordinated and strategic approach to conduct well designed studies with pragmatic endpoints.
Introduction
Trauma is one of the world’s leading causes of death
and disability. Around 40% of deaths are due to bleeding
or its consequences, establishing hemorrhage as the
most common cause of preventable death in this clinical
group [1-3]. The relationship between trauma hemor-
rhage and poor outcomes has been well recognized for
over 30 years [4], and applies globally [5,6], in both civi-
lian and military settings [7]. However, outcomes from
severe hemorrhage remain poor, with mortality rates
approaching 50% for patients who require massive blood
transfusion or who develop a significant coagulopathy
[8,9]. Management of trauma hemorrhage depends on a
multifactorial approach of timely surgical intervention,
fluid resuscitation and blood transfusion therapy [10].
Advances have taken place in our understanding of
the pathophysiology of trauma induced coagulopathy
[11,12], in the availability of rapid diagnostic modalities
[13], and the introduction of hemostatic resuscitation
strategies [14]. Conversely, evidence reviews have shown
that some accepted therapies such as blood or plasma
transfusion may be ineffective or associated with worse
outcomes [15,16].
Existing reviews have focused on individual interven-
tions, such as transfusion ratios [16-19], blood substi-
tutes [20], or pharmaceutical agents [21,22]. Our
objective was to conduct a systematic review of the
wider trial literature for all randomized controlled trials
(RCTs) relevant to the early management of trauma
patients with bleeding. We specifically aimed to appraise
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the methodology of the trials and to assess a broad
range of outcomes focusing on bleeding and transfusion
requirements, correction of coagulopathy and mortality.
Materials and methods
Search strategy
We followed a study specific protocol for this systematic
review. All RCTs relating to early management of
hemorrhage, transfusion or traumatic coagulopathy in
severely injured patients of any age were considered for
inclusion. No language restrictions were set. MeSH
index and free text terms combined with RCT filters
were used to search MEDLINE (1950 to July 2010),
EMBASE (1980 to July 2010), and CENTRAL (The
Cochrane Library Issue 7, 2010). We searched the
ongoing trial registers: Current Controlled Trials, Clini-
calTrials.gov and the World Health Organization Inter-
national Clinical Trials Registry Platform (ICTRP). The
National Health Service Blood and Transplant Systema-
tic Review Initiative (NHSBT SRI) RCT Handsearch
Database (1980 to July 2010) and the Cochrane Injuries
Group Specialist Register were searched, and the refer-
ence lists of the identified RCTs and relevant narrative
reviews were checked for additional trials. Papers not
published in English were translated. Full details of the
search are presented in Additional file 1.
Selection criteria
Citations and abstracts identified by the searches were
screened for relevance by one reviewer. Full publications
of accepted studies were assessed by two reviewers
working independently against the inclusion/exclusion
criteria. The criteria for inclusion of full reports were: at
least 75% of the subjects were trauma patients with
bleeding or hemorrhagic shock; interventions were
applied within 24 hours of injury; the RCTs compared
treatment and placebo or alternative treatments; out-
comes reported included bleeding, blood loss, coagulo-
pathy, or transfusion requirements; and allocation of the
groups was by formal randomization or a quasi-random
method. Data were recorded on mortality and morbidity
including multi-organ failure (MOF), acute respiratory
distress syndrome (ARDS) and infection. Trials assessing
isolated traumatic brain injury or burns were excluded.
Data abstraction and quality assessment
Data were abstracted onto study specific forms by one
reviewer and verified by a second reviewer. This
included: country of origin, clinical setting, study popu-
lation, trial structure, study quality, nature and duration
of intervention and control groups, outcomes assessed
and conclusions reported. Disagreements were resolved
by consensus. Assessment of the methodological quality
of the eligible RCTs was undertaken. We assessed the
generation of random sequence, concealment of alloca-
tion, blinding of allocation and incomplete outcome
data [23].
Analysis
We performed a descriptive analysis as it was not possi-
ble to undertake a meta-analysis due to the heterogene-
ity of the interventions. The RCTs were grouped into
four clinical areas: blood and blood saving strategies;
mechanical and surgical management; use of intrave-
nous fluids for resuscitation; and pharmaceutical agents.
Results
The search strategy identified 11,856 citations. A total of
120 citations were relevant and reviewed at full text.
After exclusions (Figure 1) [24], 35 completed RCTs
were eligible for analysis (Additional file 2) [25-63]. Four
trials are ongoing [64-67] (Table 1) and three have been
terminated [68-70] (Table 2). Trials ranged in size from
32 to 20,211 participants and the majority (n = 23) were
single centre studies. Thirty-four trials were of parallel
group design and one a crossover trial [49]. Nine studies
examined a pre-hospital intervention [32,34,41-44,
47-49], one study used an intervention in both pre-hos-
pital and hospital settings [31] and the remaining inter-
ventions were administered in-hospital [25,26,29,30,33,
35-40,45,46,50-57,61-63].
The majority of trials (n = 31) recruited trauma patients
exclusively, but four studies included non-trauma patients
comprising between 4 and 25% of participants
[25,32,45,46], totalling 81 patients. All 35 studies included
civilian patients only. Six trials only recruited participants
with penetrating injuries [29,34,35,41,48,57] and one only
blunt injury [57]. The 22 studies that included both types
of injury had a mean penetrating injury rate of 37% (range
1 to 89%). Twenty-five studies provided data on injury
severity scores (ISS) of participants. The mean ISS for stu-
dies reporting ISS was 24, range 15 to 33. The inclusion
criteria for participants varied. Three studies used a systo-
lic blood pressure (SBP) below 80 mmHg [38,37,46], 15
RCTs used 90 mmHg [29,31,33,34,39-41,43,44,48,51,
52,56,61,63] and 3 studies used 100 mmHg [30,42,53].
Only one RCT used base deficit as an inclusion criterion
[61]. Seventeen studies provided data on the percentage of
participants receiving blood transfusions (overall mean
74%, range: 5 to 100%) [25,26,31,33,35,36,38,39,42,46,
55-57,61,62]. Enrolled patients receiving massive transfu-
sion (over 10 units of RBC in 24 hours) varied from 6 to
100% (mean 30%) [25,36,37,42,53,57,61].
Methodological quality is summarized in Additional
file 3 and Figure 2[71]. Only 12 studies described ade-
quate sequence generation methods. Allocation conceal-
ment was detailed in 23 studies and adequate in 13.
Twenty-one trials did not report blinding, 14 reported
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blinding of either participants or personnel and 4 of
these also reported blinding of the outcome assessor.
Most studies (n = 26) had no loss of patients, and five
had less than 10% loss to follow-up. Only one study
used good methodological practices in all areas exam-
ined [56]. There was no trend to improvement in meth-
odological quality over time.
Blood and blood saving strategies (seven trials enrolling
1,374 participants)
Seven RCTs were identified which examined blood pro-
ducts (n = 2) or blood saving strategies (n = 5). Of the
two RCTs that looked at blood product administration,
one compared platelet therapy with fresh frozen plasma
(FFP) for the prevention of microvascular bleeding [25].
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The second compared leucodepleted versus standard
blood products in terms of infection [26], micro-chimer-
ism [27], and acute lung injury [28]. Five RCTs looked at
methods of reducing allogeneic blood use. One assessed
red blood cell (RBC) salvage in abdominal injury [29] and
four trials evaluated a blood substitute, (PolyHeme,
Northfield Laboratories Inc., Evanston, Illinois, USA
[30,31] or diaspirin cross-linked hemoglobin - DCLHb,
Baxter Healthcare, Round Lake, Illinois, USA [32,33]).
Mortality rates were not affected by platelet adminis-
tration [25], leucodepleted blood products [26], or cell
salvage [29]. Only two of the four blood substitute
RCTs reported mortality and neither identified a differ-
ence in outcome [31,33]. Three of the blood substitute
studies reported morbidity outcomes (MOF, ARDS or
infection) with no significant findings [31-33].
Transfusion requirements were reduced by cell salvage
at 24 hours [29]. Three of the blood substitute studies
also reported a significant reduction in RBC requirements
[30,31,33]. The fourth study of DCLHb did not report
transfusion use [32]. There was no difference in micro-
vascular bleeding in the RCT comparing platelet and FFP
transfusions [25].
Four trials reported coagulation outcomes
[25,29,31,32]. Neither platelet transfusion, when com-
pared to FFP [25], nor cell salvage [29] led to any signif-
icant improvement in coagulation. DCLHb did not
affect activated partial thromboplastin time (APTT)
[32], but patients receiving PolyHeme had significantly
increased rates of prolonged prothrombin time (PT) and
APTT, although an imbalance in these parameters was
seen at the time of randomization [31].
Mechanical and surgical management. (two trials
enrolling 257 participants)
Only two RCTs were identified. One study examined the
use of Pneumatic Anti-Shock Garments (PASG) for
traumatic injury [34] and a second investigated whether
vascular control of renal vessels during surgery for kid-
ney injury altered outcome [35].
Table 1 On-going studies
On-going study Clinical group of trauma
patients
Intervention
details
Comparator
details
Primary
endpoint
Target
number to
be
recruited
Expected
end date
CRISTAL: Colloids versus crystalloids
for resuscitation of critically ill
patients
ITU patients, fluid
resuscitation
Colloids Crystalloids 28 day
mortality
3,010 March
2011
High versus low MAP for trauma
patients undergoing surgery
Adults, SBP < 90 mmHg,
requiring laparotomy or
thoracotomy,
Target minimum
mean arterial BP
50 mmHg
Target minimum
mean arterial BP
65 mmHg
30 day
survival
271 July 2011
FIRST: Colloids versus crystalloids for
resuscitation of trauma patients
Adults, requiring ≥3 litres
of fluid
HES 130/0.4 in
saline (Voluven)
0.9% saline Fluid
volumes
over first 24
hours
140 December
2009
Formula-driven vs. laboratory-guided
transfusion in bleeding trauma
patients: a feasibility study
Adults, requiring four units
of RBC in two hours and
ongoing blood loss
FFP:RBC:platelets
ratio of 1:1:1 -
formula
Standard of care Protocol
compliance
at 12 hours
70 October
2011
FFP, fresh frozen plasma; GCS, Glasgow coma score; ITU, intensive care unit; MAP, mean arterial pressure; RBC, red blood cell; SBP, systolic blood pressure.
Table 2 Terminated studies
Study Clinical group of
trauma patients
Intervention details Comparator
details
Primary
endpoint
Completion/Termination date
Warming techniques
for treatment of
hypothermia in
polytrauma
Adults, polytrauma,
GCS > 9, ISS > 16
and ASCOT score =
2 to 50%
Endovascular catheter
+ forced air warming
Forced air
warming
Morbidity
during
length of
stay
Suspended July 2010. Insufficient numbers
of patients recruited
Hypertonic fluids for
resuscitation of
hypovolemic shock
Adults, prehospital
SBP ≤ 70, or
prehospital SBP 71-
90 and HR ≥108
Arm A: 7.5%
hypertonic saline/6%
Dextran-70 Arm B:
7.5% hypertonic saline
three arm trial
Arm C: 0.9%
normal saline
28-day
survival
Terminated August 2009 - no difference in
28-day survival (futility). Analysis reported
earlier but not higher mortality with
hypertonic saline arms.
Low dose vasopressin
versus placebo in
Traumatic Shock
Resuscitation
Adults, SBP < 90
mmHg
Bolus vasopressin 4 U,
then continuous
infusion 2.4 U/hour for
five hours
Normal saline To develop
new
resuscitation
regimens
Terminated April 2009 - poor accrual rate
ASCOT, a severity characterization of trauma score; rFVIIa, recombinant activated factor VII; SBP, systolic blood pressure.
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There was a trend to increased mortality in those
patients treated with PASG [34]. Transfusion require-
ments were not altered by either intervention [34,35]
and intra-operative blood loss was similarly unaffected
during surgery for renal trauma [35]. Neither study
reported coagulation results.
Use of intravenous fluids for resuscitation (18 trials
enrolling 3,394 participants)
Twelve of 18 studies compared different resuscitation
fluids: colloid vs. colloid (n = 1) [36]; colloid vs. crystal-
loid (n = 4) [37-40]; or crystalloid vs. hypertonic saline
+/-dextran (HSD) (n = 7) [41-47]. The remaining six
studies examined fluid administration strategies, includ-
ing immediate vs. delayed (two RCTs) [48,49]; continu-
ous arteriovenous rewarming (CAVR) (one RCT) [50];
and achievement of hemodynamic goals (three RCTs)
[51-53]. The hemodynamic endpoint RCTs evaluated
various interventions; the achievement of a certain sys-
tolic blood pressure (SBP) using a rapid infusion system
[51]; a high or low SBP endpoint [52]; and the effect of
increased hemodynamic monitoring against standard
care [53].
Mortality was reduced at 24 hours and 30 days with
HSD [46], but this was not reproduced in the six other
HSD studies [41-45,47]. Delayed fluid administration led
to a significant improvement in survival to hospital dis-
charge in one of two studies on timing of fluid therapy
[48]. The second study did not find any mortality differ-
ence [49]. No RCT of hemodynamic endpoints identified
any significant mortality differences [51-53]. CAVR led
to a significant reduction in mortality at 24 hours but
no difference at hospital discharge [50].
Seven of 18 trials reported other clinical outcomes.
Five evaluated the development of ARDS [37,48-51]. A
significant increase was reported following albumin
administration [37] and a trend was seen with CAVR
[50]. Two studies reported MOF, both showing no dif-
ference between study arms [36,53]. Five RCTs reported
infection data [36,48-50,53] but only Plasma Protein
Fraction (PPF) infusion showed a significant difference
[36].
There was no difference in transfusion requirements
in 10 of the 12 RCTs examining type of fluid adminis-
tered [36-39,41-44,46,47]. A significant reduction in
RBC use was reported at one hour with pentastarch [40]
Figure 2 Risks for bias in included RCTs. We assessed study risk for bias according to recommendations from the Cochrane Collaboration [23].
*Whether the study reported methods of randomization sufficiently to meet current CONSORT guidelines for true random allocation of
participants [71]. ^ Whether the study reported methods to conceal allocation sufficiently to determine whether the chosen intervention for a
participant could have been predicted in advance. † Whether the study reported methods by which patients, staff or assessors were prevented
from knowing the intervention given to each participant. ‡ Whether the study described loss-to-follow up figures.
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and throughout resuscitation with hypertonic solutions
[45]. Transfusion requirements were not affected by
timing of fluids [48,49]. Of the three RCTs examining
hemodynamic endpoints only the rapid infuser showed
a significant reduction in RBC transfusion and only in
the first hour [51] CAVR did not affect blood product
use [50].
Clotting parameters were reported in seven of these
RCTs [36,39,43,44,48,50,51]. Three studies showed a dif-
ference: a higher APTT was seen on days 1 to 2 in
patients receiving Hetastarch (HES) compared to PPF,
but no difference in PT [36]; APTT was improved at 5
to 10 hours in patients receiving fluids via a rapid infu-
sion system [51]; and there was a significantly prolonged
PT and APTT in patients receiving immediate com-
pared to delayed fluid therapy, but no significant differ-
ence after operative intervention [48].
Pharmaceutical agents (eight trials enrolling 21,689
participants)
Three of eight pharmaceutical trials reported effects of
antifibrinolytics in trauma [54-56]. Aprotinin was com-
pared to heparin [54] and to placebo [55] and tranexa-
mic acid was compared to placebo [56]. Two RCTs
(published as one paper [57]) reported the effects of
recombinant factor VIIa (rFVIIa) in blunt and penetrat-
ing injury. Three post-hoc subgroup analyses [58-60]
were published from these original data. A phase III
RCT examining the efficacy of rFVIIa in the manage-
ment of traumatic hemorrhage has been recently pub-
lished [61]. Two RCTs looked at novel drugs examining
the effects of a bactericidal protein (rBPI21) [62] and a
monoclonal antibody (rhuMAb CD18) [63].
All pharmaceutical trials reported a mortality out-
come. There was a significant reduction in death due to
bleeding and all cause mortality in trauma patients
receiving tranexamic acid [56]. The two small aprotinin
RCTs did not identify a mortality benefit [54,55]. rFVIIa
administration did not affect mortality [57,58,61]. A
trend towards reduced mortality was reported at day 15
following administration of rBPI21 [62].
Five trials reported other clinical outcomes. Results
from the phase II rFVIIa study reported no difference in
MOF rates for blunt injury [57], and a trend to reduc-
tion of MOF in the penetrating [57], and the coagulo-
pathic subgroups [58]. For those patients surviving more
than 48 hours, there was a significant reduction in MOF
rates in blunt trauma [59]. The phase III rFVIIa study
reported a trend to reduction of MOF for blunt injury
[61]. ARDS rates were significantly reduced in the inter-
vention arms in three RCTs; rFVIIa in blunt injury [57]
and the coagulopathic subgroup [58], aprotinin in pul-
monary insufficiency [55] and rhuMAb CD18 [63]. A
trend to reduction of ARDS was reported in the recent
rFVIIa RCT in blunt injury [61]. Rates of sepsis were
unaffected by rFVIIa in either injury group in this same
study [61].
Transfusion outcomes were reported in one of the
three RCTs of antifibrinolytic agents [56]. Transfusion
use was not altered over a 28-day period following
administration of tranexamic acid. In contrast, rFVIIa
led to a significant reduction in RBC [57,61] and FFP
[61] requirements in blunt injury and a trend to reduc-
tion of RBC [57] or total allogeneic transfusion [61] use
in penetrating injury. In the coagulopathic subgroup a
significant reduction in RBC and FFP use and a trend to
a reduction in platelet use was reported at 48 hours
[58]. Patients treated with rFVIIa and placebo received
significantly greater numbers of massive transfusions if
their post-study drug PT remained elevated at one hour
[60]. Neither RCT examining novel drugs showed a dif-
ference in transfusion requirements [62,63].
Little coagulation data were presented from the antifi-
brinolytic studies, and none from the novel drug RCTs.
In the study where heparin was compared to aprotinin
the heparin group was reported to have higher factor
assay levels up to day 7 [54]. The RCTs examining
rFVIIa in trauma originally did not report coagulation
data [57]. In a subsequent report, rFVIIa reduced the
mean PT and antithrombin and fibrinogen levels were
significantly lower in patients with PT values > 18s [60].
The phase III rFVIIa study reported no difference in dis-
seminated intravascular coagulation (DIC) rates between
rFVIIa and placebo [61].
Discussion
The 35 RCTs identified might be expected to provide a
strong evidence base for a single clinical condition.
However, the multifactorial nature of trauma hemor-
rhage, the multiplicity of interventions, issues with trial
design, difficulties with the conduct of trauma trials and
lack of a coordinated approach mean that only limited
conclusions can be drawn. The largest sub group of
included RCTs evaluated different strategies for using
fluids during resuscitation, but did not consistently iden-
tify improvements in outcomes. The RCTs evaluating
hemoglobin substitutes reported a reduction in RBC
requirements but safety remains a concern [20]. Very
few studies were identified evaluating the clinical effec-
tiveness of RBC or blood component therapy. Only two
studies were identified which evaluated surgical or
mechanical interventions, which is surprising given the
interest in damage control surgery [72] and angio-embo-
lization [73]. Tranexamic acid was the only pharmaceu-
tical agent that improved mortality [56].
Two studies reported bleeding endpoints using time
taken to achieve hemorrhage control as their endpoint
[37,52], all other studies reported surrogate outcomes.
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Transfusion requirement was commonly used as a sur-
rogate outcome for bleeding, but its use introduces
issues with variations in transfusion practice, differences
in product type and availability, and survivor bias [74].
Although transfusion for trauma hemorrhage is usually
completed within a few hours of injury [75], a large pro-
portion of the transfusion data was reported over a
much longer timeframe. Differentiation between early
and late transfusion use is an important distinction in
understanding the effects of interventions for acute
bleeding.
There was no demonstrable association between survi-
val and transfusion requirements, despite evidence from
observational studies [76,77]. None of the nine trials
reporting a reduction in RBC use had an associated sur-
vival improvement [29-31,33,39,45,51,57,61]. Conversely,
other studies reported survival benefits but did not
observe differences in transfusion use [46,48,56]. No
study used correction of coagulopathy as a defined end-
point. Newer methods of assessing hemostasis such as
thromboelastography were not used and a definition of
coagulopathy was variable and provided by a limited
number of trials [32,58,60].
Many of the included trials were poorly designed or
conducted, underpowered or recruited small numbers of
participants. Recruitment to trauma RCTs can be diffi-
cult, not least because of the challenges of enrolling
incapacitated patients where informed consent is impos-
sible, although some countries now have recognized
processes for emergency consenting. Low patient num-
bers affect study power and increase the risk of bias,
since baseline imbalances between patient groups is
likely to occur even if randomization has been rigorous
[78]. Only five studies were powered to provide mortal-
ity results, and it is likely that the improvement in mor-
tality suggested by the sample size calculations (ranging
between 6 and 35%) was over optimistic in many studies
[79]. In contrast the CRASH-2 study tested the hypoth-
esis that tranexamic acid would provide a 2% survival
benefit which projected a sample size of 20,000 partici-
pants [56].
There are limitations to this review. A quantitative
analysis was not possible because of the heterogeneity
between studies. For example, the inclusion criteria for
patients varied widely, such as SBP values for shock.
This increases the risk of missing low levels of benefit
or harm, which were not large enough to be statistically
relevant in any single RCT. The heterogeneity also high-
lights the importance of working towards uniformity in
clinical trials. Attempts were made to identify all rele-
vant RCTs including those in the non-English literature,
but some studies may have been missed. Our literature
search spanned 60 years, a time frame which has seen
trauma care alter significantly. The included RCTs are
all from civilian settings, and, therefore, RCT data do
not exist to evaluate changes in military practice,
although the recent changes in transfusion support for
trauma patients have been driven by military data.
There were no eligible RCTs examining, for example,
the role of tourniquets and, therefore, this area has not
been addressed in our review, although RCTs may not
be indicated for every intervention.
Conclusions
The acute management of trauma hemorrhage has been
evaluated in a large number of trials but these have not
in the main produced results that have changed man-
agement or improved outcomes. This systematic review
set out to examine RCTs, as the most robust form of
study design and in so doing observational data have
not been identified and appraised. However, it demon-
strates that the difficulties associated with recruitment,
design and conduct of trauma trials can be overcome to
produce better quality RCTs. As our understanding of
the pathophysiology of trauma hemorrhage grows, a
coordinated strategy is required for this globally impor-
tant condition.
Key messages
• A total of 35 RCTs were identified relating to the
management of trauma haemorrhage, but due the
multifactorial nature of hemorrhage, the multiplicity
of the RCT interventions, issues with trial design
and difficulties with the conduct of trauma trials,
only limited conclusions could be drawn.
• The RCT literature did not demonstrate a correla-
tion between reduction of transfusion requirement
and improvement in the survival of their partici-
pants, even though the observational literature has
reported such an association.
• Large, well-conducted studies with pragmatic end-
points are required to improve our understanding of
the complex interplay between bleeding and coagu-
lopathy, transfusion requirements and mortality.
• The CRASH-2 study has confirmed that large,
well-conducted trauma studies are achievable.
Additional material
Additional file 1: Search strategy. This file contains full documentation
of the comprehensive search strategy completed for this systematic
review.
Additional file 2: Included randomized controlled trials. This file
contains a table listing all the included RCTs within this systematic
review, including groups of patients examined, intervention and
comparator arms and main clinical outcomes of each study.
Additional file 3: Quality assessment of included published
randomized controlled trials. This file includes a table detailing the
quality assessment of all included RCTs in this systematic review. It
Curry et al. Critical Care 2011, 15:R92
http://ccforum.com/content/15/2/R92
Page 7 of 10
particularly focusses on sequence generation, allocation concealment,
blinding and incomplete outcome data.
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